Betamethasone Shortage: What Providers and Prescribers Need to Know in 2026

Betamethasone remains a cornerstone of dermatologic, rheumatologic, and allergy practice. While the drug is not facing a formal FDA-listed shortage in 2026, providers in several specialties are fielding calls from patients who cannot fill prescriptions. This clinical briefing covers the current supply landscape, prescribing implications, and practical strategies to maintain patient access.

Current Supply Status (2026)

As of 2026, neither the FDA Drug Shortage Database nor the ASHP Drug Shortage Resource Center lists betamethasone topical or systemic formulations as nationally short. Generic betamethasone dipropionate and betamethasone valerate are manufactured by multiple companies including Taro, Perrigo, Actavis, and others, providing meaningful supply redundancy.

However, three specific supply pressures are generating patient access friction:

1. Formulation-specific stock gaps: The branded Luxiq foam (betamethasone valerate 0.12%) and Sernivo spray (betamethasone dipropionate 0.05%) have limited generic competition and limited pharmacy shelf presence.
2. Injectable demand surge: Ongoing shortages of triamcinolone acetonide injection (Kenalog) and intermittent Depo-Medrol shortages have prompted many providers to switch to Celestone Soluspan, increasing demand for injectable betamethasone.
3. Distributor-level gaps: Retail chains dependent on a single regional distributor may face temporary stockouts affecting multiple stores simultaneously.

Prescribing Strategies to Minimize Patient Access Issues

1. Write for the Generic, Not the Brand

Prescriptions specifying brand-name Diprolene, Luxiq, or Sernivo with "Dispense As Written" (DAW) limit pharmacy fill options significantly. Unless there's a clinical reason for a specific brand or formulation, writing for "betamethasone dipropionate 0.05% cream" or "betamethasone valerate 0.1% ointment" (generic names + form) maximizes pharmacy substitution options and fill rates.

2. Specify Formulation Flexibility Where Clinically Appropriate

For many dermatologic indications, the clinical outcome difference between cream and ointment is modest. For body plaques, adding "may dispense cream or ointment" to the prescription allows the pharmacy to substitute the available vehicle. Where formulation does matter (e.g., scalp, moist intertriginous areas), specify accordingly.

3. Therapeutic Alternatives by Potency Class

When betamethasone is unavailable, the following alternatives provide comparable clinical options:

• Class 1 (super-potent) alternatives to augmented betamethasone dipropionate: Clobetasol propionate 0.05% cream/ointment/foam; halobetasol propionate 0.05% cream/ointment
• Class 2 alternatives to betamethasone dipropionate: Fluocinonide 0.05% cream/ointment/gel; desoximetasone 0.25% cream/ointment
• Class 3–4 alternatives to betamethasone valerate: Triamcinolone acetonide 0.1% cream/ointment (Class 4–5); mometasone furoate 0.1% cream/ointment (Class 4)

4. Injectable Betamethasone (Celestone Soluspan): Practical Notes

Celestone Soluspan (betamethasone sodium phosphate 3 mg/mL + betamethasone acetate 3 mg/mL = 6 mg/mL total betamethasone) is the only commercially available corticosteroid with both a rapid-acting (sodium phosphate) and depot (acetate) component in a single vial. This dual action makes it valuable for conditions where rapid onset and sustained effect are both desired.

If Celestone Soluspan is unavailable at your preferred supplier, the following alternatives are commonly used:

• Triamcinolone acetonide (Kenalog 10 or 40 mg/mL): Widely available depot injectable; primary alternative for intra-articular and soft tissue injections. Note: Kenalog itself faces periodic shortage conditions (see ASHP shortage database).
• Methylprednisolone acetate (Depo-Medrol 40 or 80 mg/mL): Another depot option for joint injections. Has also faced intermittent shortages.
• Dexamethasone: Potent, rapid-acting but lacks depot effect. Shorter duration of action. Appropriate for acute conditions but not ideal for sustained joint relief.

Glucocorticoid Equivalency Reference

When converting between systemic corticosteroids, these anti-inflammatory equivalencies are standard references:

• Betamethasone 0.6 mg ≈ Dexamethasone 0.75 mg ≈ Methylprednisolone 4 mg ≈ Prednisone 5 mg ≈ Hydrocortisone 20 mg

Important: These equivalencies apply to systemic anti-inflammatory potency only. Mineralocorticoid effects, duration of action, and pharmacokinetic profiles differ. Clinical judgment is required for specific patient populations.

Documentation and Billing Considerations

When switching a patient from betamethasone to an alternative, document: (1) the clinical rationale for betamethasone, (2) the reason for the switch (e.g., "pharmacy unable to obtain requested formulation"), (3) the alternative selected, and (4) patient education provided. For intra-articular injection alternatives, note the drug, dose, concentration, route, and joint injected as usual. This documentation supports prior authorization renewal processes and continuity of care across providers.

Tools for Providers: Checking Real-Time Availability

To help your patients locate betamethasone — and reduce the number of callbacks your office receives about unfilled prescriptions — consider directing them to medfinder for providers. medfinder contacts pharmacies in real time to verify stock, helping patients quickly identify where their prescription can be filled without burdening your staff.

Summary for Providers

Betamethasone is not in a national shortage, but prescribing flexibility and proactive patient communication can significantly reduce access friction. Defaulting to generic names, allowing vehicle substitution where clinically safe, and being prepared with a tier of alternatives will minimize prescription rework and patient delays. For a more detailed workflow guide, see how to help your patients find betamethasone in stock.